
|Articles|July 20, 2022
Daily Medication Pearl: Hyqvia Immune Globulin Infusion 10%
Author(s)Saro Arakelians, PharmD
Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.
Advertisement
Medication Pearl of the Day: Hyqvia Immune Globulin Infusion 10%
Indication: Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency (PI) in adults.
Insight:
- Dosing: May start from 7.5 g up to 30 g infusions depending on the patient.
- Dosage forms: Comes in 10%, 2.5, 5-, 10-, 20-, and 30-gram proteins.
- Adverse events: The most common adverse reactions observed in clinical trials in >5% of subjects were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.
- Mechanism of action: The immune globulin infusion 10% (human) provides the therapeutic effect of Hyqvia. The recombinant human hyaluronidase of Hyqvia increases dispersion and absorption of the immune globulin infusion 10% (human). The immune globulin infusion 10% (human) of Hyqvia supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
FDA Approves Blenrep for Treatment of Relapsed or Refractory Multiple Myeloma
3
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
4
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
5














































































































































































































